This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
CD33 CAR-T Program
Drug Names(s): CD33-Specific Chimeric Antigen Receptor
Description: Intrexon, ZIOPHARM Oncology, and Merck, with The University of Texas MD Anderson Cancer Center, are developing a CD33-specific chimeric antigen receptor (CAR) therapy.
Ziopharm and Intrexon
In January 2011, Ziopharm and Intrexon announced a global exclusive channel partnership in oncology where Ziopharm will develop and commercialize DNA based therapeutics using Intrexon's UltraVector Technology. Under the partnership, Ziopharm will utilize Intrexon's transgene engineering platform for the controlled and precise cellular production of anti-cancer effectors. Ziopharm will have rights to Intrexon's entire human in vivo effector platform within the field of oncology which includes INXN-2001/1001.
The exclusive channel partnership between Intrexon and Ziopharm has been established specifically for the field of human oncologic therapeutics. Under the partnership, Intrexon remains responsible for technology discovery efforts and managing the patent estate as well as for certain aspects of manufacturing. Ziopharm will be responsible for conducting preclinical and clinical development of candidates, as well as for other aspects of...See full deal structure in Biomedtracker
Partners: Merck KGaA ZIOPHARM Oncology, Inc. University of Texas MD Anderson Cancer Center
CD33 CAR-T Program News
Additional information available to subscribers only: